We are live on ! Find out more
EU

Emory University Portfolio holdings

AUM $160M
1-Year Est. Return 8.57%
This Fund
S&P 500
This Quarter Est. Return
-14.41%
1 Year Est. Return
+8.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$127M
AUM Growth
-$25.9M
Cap. Flow
-$1.77M
Cap. Flow %
-1.39%
Top 10 Hldgs %
51.19%
Holding
54
New
8
Increased
16
Reduced
16
Closed
8

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.47M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$2.42M
3
AMRN
Amarin Corp
AMRN
+$2.36M
4
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$2.34M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$2.29M

Top Sells

Rank Stock Value
1
DBVT
DBV Technologies
DBVT
+$3.11M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$2.96M
3
ECYT
Endocyte, Inc. Common Stock
ECYT
+$2.64M
4
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$2.58M
5
SAGE
Sage Therapeutics
SAGE
+$2.54M

Sector Composition

Rank Sector Weight
1 Healthcare 48.32%
2 Financials 34.37%
3 Consumer Discretionary 6.74%
4 Industrials 2.63%
5 Real Estate 1.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DOVA
51
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
– –
-116,146
Closed -$2.44M
TFCF
52
DELISTED
Twenty-First Century Fox, Inc. Class B
TFCF
– –
-48,194
Closed -$2.21M
ECYT
53
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-148,628
Closed -$2.64M
BHVN
54
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-78,838
Closed -$2.96M
1 2
3

Similar funds

SGCM
Sanchez Gaunt Capital Management Reno, Nevada $160M AUM
LCA
Legend Capital Advisors New York $160M AUM
SMF
Sterling Manor Financial Saratoga Springs, New York $160M AUM 13.84% 1-Year Est. Return
PCC
Perry Creek Capital New York $160M AUM 3.05% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
RCWM
Royal Capital Wealth Management Carmel, Indiana $161M AUM 18.42% 1-Year Est. Return
BFAG
Blackston Financial Advisory Group The Villages, Florida $160M AUM 16.38% 1-Year Est. Return
SLG
Sanchez Levi Garrett $159M AUM

Emory University's Q4 2018 Portfolio in Review

As of Q4 2018, Emory University held 54 positions worth $127M, down 17% from $153M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Emory University's Q4 2018 filing shows 8 new, 16 increased, 16 reduced and 8 closed positions. Its largest new stake was BioCryst Pharmaceuticals: 317,745 shares worth $2.56M. The largest sale was DBV Technologies, an estimated $3.11M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 50% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Emory University's largest Q4 2018 buy was BioCryst Pharmaceuticals: 317,745 shares worth $2.56M.
  • Emory University added most to Madrigal Pharmaceuticals in Q4 2018, an estimated $874K increase.
  • Emory University's biggest Q4 2018 reduction was Acadia Pharmaceuticals, cutting an estimated $1.44M.
  • Emory University fully exited DBV Technologies in Q4 2018, selling an estimated $3.11M.
  • Emory University's ten largest holdings make up 51% of its $127M portfolio in Q4 2018.
  • Emory University opened 8 new positions and closed 8 in Q4 2018.
  • Emory University's portfolio value fell 17% quarter-over-quarter to $127M.

Based on Emory University's 13F filing for Q4 2018, filed 12 Feb 2019.